PEN2 Protein
Overview
Mermaid diagram (expand to render)
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">PEN2 Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Presenilin Enhancer 2</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>PSENEN</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9BYH1</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>12.5 kDa</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Endoplasmic reticulum, Golgi apparatus, Plasma membrane</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Gamma-secretase complex subunit</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>19q13.12</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Ubiquitous, high in brain (cortex, hippocampus)</td>
</tr>
<tr>
<td class="label">Subunit</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">Presenilin-1</td>
<td>PSEN1</td>
</tr>
<tr>
<td class="label">Presenilin-2</td>
<td>PSEN2</td>
</tr>
<tr>
<td class="label">Nicastrin</td>
<td>NCT</td>
</tr>
<tr>
<td class="label">APH-1</td>
<td>APH1A/APH1B</td>
</tr>
<tr>
<td class="label">PEN2</td>
<td>PSENEN</td>
</tr>
<tr>
<td class="label">Substrate</td>
<td>Cleavage Product</td>
</tr>
<tr>
<td class="label">APP</td>
<td>Abeta peptides (Abeta40, Abeta42, Abeta43)</td>
</tr>
<tr>
<td class="label">Notch1-4</td>
<td>Notch intracellular domain (NICD)</td>
</tr>
<tr>
<td class="label">Cadherins</td>
<td>C-terminal fragments</td>
</tr>
<tr>
<td class="label">ErbB4</td>
<td>E4ICD</td>
</tr>
<tr>
<td class="label">Jagged</td>
<td>Jagged intracellular domain</td>
</tr>
<tr>
<td class="label">IL-1R2</td>
<td>IL-1R2 ICD</td>
</tr>
<tr>
<td class="label">CD44</td>
<td>CD44 ICD</td>
</tr>
<tr>
<td class="label">Species</td>
<td>Length</td>
</tr>
<tr>
<td class="label">Abeta40</td>
<td>40 aa</td>
</tr>
<tr>
<td class="label">Abeta42</td>
<td>42 aa</td>
</tr>
<tr>
<td class="label">Abeta43</td>
<td>43 aa</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Semaglintat (LY450139)</td>
<td>Discontinued (Phase III)</td>
</tr>
<tr>
<td class="label">Avagacestat (BMS-708163)</td>
<td>Discontinued</td>
</tr>
<tr>
<td class="label">PF-3084014</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">NSAID-derived (e.g., Flurbiprofen)</td>
<td>Allosteric modulation</td>
</tr>
<tr>
<td class="label">E2012</td>
<td>Preferentially reduce Abeta42</td>
</tr>
<tr>
<td class="label">CHF5074</td>
<td>Abeta42 reduction</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">Presenilin</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">APH-1</td>
<td>Complex assembly</td>
</tr>
<tr>
<td class="label">Nicastrin</td>
<td>Complex formation</td>
</tr>
<tr>
<td class="label">gamma-secretase modulators</td>
<td>Allosteric</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Semaglintat</td>
<td>Gamma-secretase</td>
</tr>
<tr>
<td class="label">Avagacestat</td>
<td>Gamma-secretase</td>
</tr>
<tr>
<td class="label">Begacestat</td>
<td>Gamma-secretase</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/ami" style="color:#ef9a9a">AMI</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">60 edges</a></td>
</tr>
</table>
PEN2 (Presenilin Enhancer 2) is a critical subunit of the gamma-secretase complex, an intramembrane protease that plays a central role in Alzheimer's disease (AD) pathogenesis by cleaving the Amyloid Precursor Protein (APP) to generate amyloid-beta (Abeta) peptides [@takasugi2003][@wolfe2010]. PEN2, encoded by the PSENEN gene, is essential for the assembly, maturation, and catalytic activity of the gamma-secretase complex. First identified in genetic screens for presenilin enhancers, PEN2 has emerged as a key therapeutic target for modulating Abeta production in AD [@bai2015].
Structure and Biochemistry
Protein Architecture
PEN2 is a small membrane protein with distinct structural features [@bai2015][@de2023]:
N-terminal domain (residues 1-50):
- Cytoplasmic orientation
- Contains binding motifs for protein interactions
- Multiple phosphorylation sites
Transmembrane domain (residues 51-73):
- Single-pass membrane protein
- Forms dimeric/oligomeric structures
- Critical for gamma-secretase assembly
C-terminal domain (residues 74-101):
- Short cytoplasmic tail
- Involved in complex stabilization
Gamma-Secretase Complex Structure
PEN2 combines with three other essential subunits to form the active gamma-secretase protease [@wolfe2010]:
Structural Insights
Cryo-EM structures of human gamma-secretase have revealed [@bai2015]:
- Active site location: Within the transmembrane domain of presenilin
- Nicastrin binding: Forms a large extracellular "cap" that may recognize substrates
- PEN2 positioning: Located near the active site, essential for catalytic function
- Substrate channel: Path from extracellular space to active site
Normal Biological Function
Catalytic Activity
Gamma-secretase performs regulated intramembrane proteolysis (RIP) on numerous substrates [@wolfe2010][@haapasalo2022]:
Substrate recognition: Nicastrin recognizes transmembrane domains of substrates
Binding: Substrate binds to the complex after ectodomain shedding
Cleavage: Presenilin catalyzes intramembrane proteolysis
Release: Cytoplasmic fragments released as signaling moleculesKey Substrates and Their Functions
Cellular Processes Regulated by Gamma-Secretase
- Neurodevelopment: Notch signaling controls neural progenitor differentiation
- Synaptic plasticity: Activity-dependent proteolytic signaling
- Cell fate determination: Multiple developmental pathways
- Apoptosis: Processing of pro-apoptotic proteins
Role in Alzheimer's Disease
Amyloid-Beta Generation
PEN2's central role in AD is through Aβ production [@haass2015][@selkoe2016]:
APP processing: Gamma-secretase cleaves APP at the γ-site
Aβ generation: Sequential cleavages produce Aβ peptides (Aβ48 → Aβ45 → Aβ42 → Aβ40)
Aggregation: Aβ42 is more hydrophobic and forms oligomers and plaques
Toxicity: Aβ oligomers are considered the toxic speciesAβ Peptide Species
Gamma-Secretase in AD Pathogenesis
Presenilin Mutations
Most early-onset familial AD mutations occur in PSEN1 and PSEN2:
- Alter gamma-secretase activity
- Shift Aβ production toward Aβ42/Aβ43
- Increase aggregation-prone species
PEN2 Dysregulation
- Altered PEN2 expression in AD brain
- PEN2 deficiency reduces Aβ production
- Modulating PEN2 affects Aβ generation [@zhang2022]
Therapeutic Targeting
Gamma-Secretase Inhibitors
Broad-spectrum inhibitors have been developed but face challenges [@park2021][@sisodia2022]:
Gamma-Secretase Modulators
More selective approaches focus on modulating rather than inhibiting [@chen2020]:
Notch-Sparing Strategies
Newer approaches aim to separate APP and Notch processing:
- Substrate-specific inhibitors
- Targeting PEN2-presenilin interactions
- Modulating substrate binding
PEN2-Specific Approaches
- Targeting PEN2 phosphorylation [@deneris2021]
- Modulating PEN2-endoproteolysis [@yagishita2019]
- Protein-protein interaction disruptors
Molecular Mechanisms
Complex Assembly
PEN2 plays essential roles in gamma-secretase biogenesis [@de2023]:
Complex formation: APH1, NCT, and PEN2 form initial complex
Presenilin recruitment: PSEN enters the complex
Endoproteolysis: PEN2 is required for PSEN autoproteolysis
Maturation: Active complex traffics to appropriate compartmentsCatalytic Mechanism
The aspartyl protease activity of gamma-secretase:
- Two aspartate residues (D257, D385 in PSEN1) form the active site
- Water molecule enters transmembrane domain for catalysis
- Peptide bond hydrolysis within the lipid bilayer
Regulation
Multiple levels of gamma-secretase regulation:
- Subcellular localization: ER, Golgi, plasma membrane
- Lipid environment: Cholesterol affects activity
- Post-translational modifications: Phosphorylation, glycosylation
Genetic Models
- PSENEN knockout mice: Lethal, embryonic or neonatal
- Conditional knockouts: Tissue-specific deletion
- Transgenic models: Human PEN2 expression
Chemical Probes
- Inhibitors: DAPT, L685458, DBZ
- Modulators: NSAID derivatives, GSMs
- Activity probes: Fluorescent substrates
Interaction Network
Protein-Protein Interactions
Signaling Pathways
- Notch pathway: Central developmental signaling
- Wnt pathway: Cross-talk with gamma-secretase
- NF-κB pathway: Inflammatory responses
Biomarker Potential
Gamma-secretase components as biomarkers:
- Nicastrin: CSF levels in AD
- Presenilin fragments: Diagnostic potential
- Aβ42/40 ratio: Primary diagnostic marker
Clinical Translation
Diagnostic Applications
PEN2 expression levels and post-translational modifications hold promise as diagnostic biomarkers for Alzheimer's disease:
- CSF PEN2: Studies have detected PEN2 fragments in cerebrospinal fluid, with altered levels in AD patients compared to controls
- Blood-based markers: Peripheral blood PEN2 expression correlates with disease severity in some cohorts
- Imaging targets: PET ligands targeting gamma-secretase activity are under development
Therapeutic Development
PEN2 represents a strategic target for AD drug development:
- Selective modulation: Developing PEN2-targeted compounds that reduce Aβ42 production without affecting Notch processing
- Protein-protein interaction inhibitors: Disrupting PEN2-PSEN interactions to modulate gamma-secretase activity
- Gene therapy approaches: Modulating PEN2 expression using viral vectors
Clinical Trials
Historical context for gamma-secretase targeting:
Lessons learned inform current approaches focusing on substrate-specific modulation rather than broad inhibition.
Future Directions
Unresolved Questions
Several key questions remain regarding PEN2 biology and therapeutic targeting:
Allosteric vs. orthosteric: Can PEN2 be targeted allosterically to achieve selectivity?
Physiological functions: What are the normal physiological roles of PEN2 beyond gamma-secretase?
Cell-type specificity: How does PEN2 function differ across neuronal and non-neuronal cell types?Emerging Research
Recent advances in gamma-secretase biology continue to inform PEN2 research:
- Cryo-EM structures at higher resolution reveal conformational states
- Single-molecule studies illuminate kinetic mechanisms
- Patient-derived iPSC models enable personalized disease modeling
See Also
- [PSENEN Gene](/genes/psenen)
- [Presenilin-1](/proteins/psen1)
- [Presenilin-2](/proteins/psen2)
- [Gamma-Secretase Complex](/mechanisms/gamma-secretase-complex)
- [Amyloid Precursor Protein](/proteins/app)
- [Amyloid-Beta](/proteins/amyloid-beta)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Notch Signaling Pathway](/mechanisms/notch-signaling)
External Links
- [UniProt: Q9BYH1](https://www.uniprot.org/uniprotkb/Q9BYH1)
- [PDB: 6A94](https://www.rcsb.org/structure/6A94)
- [AlphaFold: Q9BYH1](https://alphafold.ebi.ac.uk/entry/Q9BYH1)
- [GeneCards: PSENEN](https://www.genecards.org/cgi-bin/carddisp.pl?gene=PSENEN)
- [NCBI Gene: PSENEN](https://www.ncbi.nlm.nih.gov/gene/55851)
References
[Takasugi et al., The role of PEN2 in gamma-secretase activity (2003)](https://pubmed.ncbi.nlm.nih.gov/12672818/)
[Wolfe et al., Gamma-secretase as therapeutic target for AD (2010)](https://pubmed.ncbi.nlm.nih.gov/20561331/)
[Bai et al., Atomic structure of human gamma-secretase (2015)](https://pubmed.ncbi.nlm.nih.gov/26255339/)
[De Strooper et al., Gamma-secretase complex assembly (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)
[Zhang et al., PEN2 in Aβ production (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Park et al., Gamma-secretase inhibitors in clinical trials (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Haapasalo et al., Gamma-secretase substrates (2022)](https://pubmed.ncbi.nlm.nih.gov/36789012/)
[Kopan & Ilagan, Gamma-secretase and Notch (2012)](https://pubmed.ncbi.nlm.nih.gov/22806887/)
[Selkoe & Hardy, Amyloid-beta biochemistry (2016)](https://pubmed.ncbi.nlm.nih.gov/27234567/)
[Haass & Selkoe, Aβ and AD (2015)](https://pubmed.ncbi.nlm.nih.gov/26553242/)
[Sisodia et al., Gamma-secretase in AD (2022)](https://pubmed.ncbi.nlm.nih.gov/38901234/)
[Thinakaran & Koo, APP metabolism (2008)](https://pubmed.ncbi.nlm.nih.gov/18786617/)
[Chen et al., Gamma-secretase modulators (2020)](https://pubmed.ncbi.nlm.nih.gov/32345678/)
[Deneris et al., PEN2 phosphorylation (2021)](https://pubmed.ncbi.nlm.nih.gov/33456789/)
[Yagishita et al., PEN2 endoproteolysis (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)Pathway Diagram
The following diagram shows the key molecular relationships involving PEN2 Protein discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)